ED
EDNSF.US Eden Research plc
- Market cap
- USD 40.1M
- P/E
- -
- P/B
- 2.42x
- ROE
- -15.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is EDNSF.US undervalued?
Graham numberThe Graham number of Eden Research plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eden Research plc fundamental analysis
No fundamental analysis for Eden Research plc yet.
Eden Research plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eden Research plc
Eden BioSolutions plc, together with its subsidiaries, biopesticides and plastic-free encapsulation technology for use in the global crop protection, animal health, and consumer products industries in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consumer p…
Full company profileEden Research plc financial statements
Eden Research plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 392K | 1.88M | 2.77M | 1.83M | 1.37M | 1.23M | 1.83M | 3.19M | 4.30M | 3.88M |
| Gross Profit | 363K | 858K | 1.54M | 862K | 9.63K | 28.3K | 207K | 1.77M | 1.87M | 1.79M |
| Operating Income | -1.89M | -1.35M | -497K | -1.36M | -2.24M | -3.21M | -2.57M | -1.87M | -2.19M | -2.29M |
| EBITDA | -1.21M | -601K | -103K | -911K | -1.90M | -2.72M | -1.86M | -6.24M | -1.59M | -1.57M |
| Net Income | -1.83M | -639K | -335K | -1.14M | -2.27M | -2.79M | -2.24M | -6.49M | -1.91M | -1.96M |
| EPS | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 7.80M | 10.6M | 9.22M | 8.86M | 16.9M | 15.0M | 12.9M | 16.6M | 15.4M | 16.3M |
| Total Liabilities | 1.03M | 2.07M | 943K | 1.52M | 2.00M | 2.20M | 2.17M | 3.05M | 3.57M | 3.91M |
| Shareholders' Equity | 6.76M | 8.51M | 8.28M | 7.34M | 14.9M | 12.8M | 10.7M | 13.5M | 11.8M | 12.4M |
| Cash & Short-term Investments | 1.53M | 3.68M | 2.48M | 502K | 7.29M | 3.83M | 1.99M | 7.41M | 3.67M | 1.52M |
| Total Debt | - | - | - | 69.5K | 415K | 398K | 355K | 230K | 169K | 672K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -806K | 230K | -702K | -1.01M | -1.02M | -1.62M | -683K | -1.70M | -1.01M | -2.40M |
| Capital Expenditure | 238K | 472K | 513K | 914K | 1.90M | 1.73M | 1.05M | 1.75M | 2.59M | 5.89K |
| Free Cash Flow | -1.04M | -242K | -1.21M | -1.93M | -2.92M | -3.34M | -1.74M | -3.41M | -3.60M | -1.98M |
| Ratios | ||||||||||
| ROE | -27.1% | -7.5% | -4.0% | -15.6% | -15.2% | -21.8% | -20.9% | -48.0% | -16.1% | -15.8% |
| ROA | -23.5% | -6.0% | -3.6% | -12.9% | -13.4% | -18.6% | -17.3% | -39.1% | -12.4% | -12.0% |
| Net Profit Margin | -467.2% | -34.0% | -12.1% | -62.7% | -165.8% | -227.0% | -122.4% | -203.5% | -44.3% | -50.4% |
| Debt to Equity | - | - | - | 0.01x | 0.03x | 0.03x | 0.03x | 0.02x | 0.01x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eden Research plc dividends
Eden Research plc has not paid dividends in the last 10 fiscal years.
Who owns Eden Research plc
- Insiders 11.25%
- Institutions 63.83%
- Public & others 24.93%
- Shares outstanding 803M
- Free float 443M
Eden Research plc company profile
- Company name
- Eden Research plc
- Ticker
- EDNSF.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 23
- Fiscal year end
- December
- Address
- 67C Innovation Drive, Abingdon, United Kingdom, OX14 4RQ
- Phone
- 44 12 8535 9555
- Website
- edenresearch.com
About Eden Research plc
Eden BioSolutions plc, together with its subsidiaries, biopesticides and plastic-free encapsulation technology for use in the global crop protection, animal health, and consumer products industries in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consumer products, such as head-lice treatment, deodorants, odour neutralizer, and fragrances, as well as food flavourings and active ingredients; and animal health products comprising companion animal, biocontrol, parasite treatments, and insect sprays. Eden BioSolutions plc was formerly known as Eden Research plc and changed its name to Eden BioSolutions plc in September 2026. The company was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.
Eden Research plc management
3- Mr. Sean Michael SmithCEO & Executive Director · born 1967
- Mr. Alexander John AbreyCFO, Secretary & Executive Director · born 1979
- Mr. Ilshad MoulanHead of Regulatory Affairs